Zacks Research Highlights Soligenix Inc.'s Upcoming Key Catalysts in Rare Disease Treatment
July 15th, 2025 6:35 PM
By: Newsworthy Staff
Soligenix Inc. is poised for significant developments in its rare disease treatment programs, with key updates and results expected in 2025 and 2026, as highlighted in a recent Zacks Small-Cap Research report.
Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has been featured in a Zacks Small-Cap Research report for its anticipated key catalysts in the latter half of 2025. The report underscores the company's progress in its phase 3 FLASH2 trial for HyBryte(TM), aimed at treating early-stage cutaneous T cell lymphoma (CTCL), with an enrollment update expected in the second half of 2025 and topline results in 2026.
Further clinical updates are anticipated in Q3 2025 for an investigator-initiated study evaluating extended HyBryte(TM) treatment, alongside topline results from phase 2a trials for SGX302 in psoriasis and SGX945 in Behcet’s disease. The Zacks report expresses optimism about these developments, suggesting they could significantly impact Soligenix's valuation, given the current share price does not fully reflect the potential upside from these programs.
For more details on the Zacks Research report, visit https://ibn.fm/QFcH6.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
